person · Reporting owner

Rowland Charles A Jr

Disclosed activity across 7 companies

Tapewire entity: 67192
SEC CIK: 0001383292

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Blueprint Medicines CorpBPMC · Entity 77326	Director	June 02, 2021	June 04, 2021
Nabriva Therapeutics Legacy plcNBRV · Entity 174291	Director	June 23, 2017	June 27, 2017
Nabriva Therapeutics plcNBRV · Entity 111497	Director	August 01, 2020	August 03, 2022
Viking Therapeutics, Inc.VKTX · Entity 4067	Director	January 02, 2026	January 05, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Blueprint Medicines Corp

Report date June 02, 2021 · Filed June 04, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	5,812	Reported balance After 2021-06-02 transaction · row 1 1 source row Row 1 · 2021-06-02 · Grant · Acquired 2,250 · Balance 5,812 F1: The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 2, 2022. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $87.13 · Expires 2031-06-02	Direct	4,500	Reported balance After 2021-06-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-06-02 · Grant · Acquired 4,500 · Balance 4,500 F2: This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 2, 2022.

Filing footnotes · ownership attribution and instrument terms

F1: The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 2, 2022. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F2: This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 2, 2022.

Nabriva Therapeutics Legacy plc

Report date June 23, 2017 · Filed June 27, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock OptionSEC Table II · derivative / convertible security · Expires 2025-07-05	Direct	16,000	Reported balance After 2017-06-23 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2017-06-23 · Other · Acquired 16,000 · Balance 16,000 F1: The exercise price is 6.618 Euro. F2: Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG. The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc. F3: This option was granted on August 26, 2016. Vesting began on August 31, 2016 and ends on August 31, 2019. This option vests on a monthly pro-rata basis at the end of each successive month following August 31, 2016.
Stock OptionSEC Table II · derivative / convertible security · Expires 2026-08-25	Direct	10,100	Reported balance After 2017-06-23 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-06-23 · Other · Acquired 10,100 · Balance 10,100 F4: The exercise price is 6.634 Euro. F2: Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG. The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc. F5: This option was granted on August 26, 2016. Vesting began on August 31, 2016 and ends on August 31, 2017. One hundred percent (100%) of the option will vest on August 31, 2017.

Filing footnotes · ownership attribution and instrument terms

F1: The exercise price is 6.618 Euro.

F2: Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG. The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc.

F3: This option was granted on August 26, 2016. Vesting began on August 31, 2016 and ends on August 31, 2019. This option vests on a monthly pro-rata basis at the end of each successive month following August 31, 2016.

F4: The exercise price is 6.634 Euro.

F5: This option was granted on August 26, 2016. Vesting began on August 31, 2016 and ends on August 31, 2017. One hundred percent (100%) of the option will vest on August 31, 2017.

Nabriva Therapeutics plc

Report date August 01, 2020 · Filed August 03, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	15,277	Reported balance After 2022-08-01 transaction · row 1 1 source row Row 1 · 2022-08-01 · Sale · Disposed 8,496 · Balance 15,277

Viking Therapeutics, Inc.

Report date January 02, 2026 · Filed January 05, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $0.00001 per shareSEC Table I · non-derivative	Direct	33,150	Reported balance After 2026-01-02 transaction · row 1 1 source row Row 1 · 2026-01-02 · Grant · Acquired 3,150 · Balance 33,150 F1: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. All shares subject to the RSU shall vest on the one year anniversary of the grant date of the award.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.42 · Expires 2036-01-02	Direct	20,400	Reported balance After 2026-01-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-01-02 · Grant · Acquired 20,400 · Balance 20,400

Filing footnotes · ownership attribution and instrument terms

F1: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. All shares subject to the RSU shall vest on the one year anniversary of the grant date of the award.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Generation Bio Co.

Report date February 09, 2026 · Filed February 09, 2026

Section 16 reporting ended · disclosed 2026-02-09. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2026-02-09 transaction · row 1 1 source row Row 1 · 2026-02-09 · Other · Disposed 53,475 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"), F2: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.87	Direct	Reported balance After 2026-02-09 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-02-09 · Disposition to issuer · Disposed 3,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an "In-The-Money Option"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.92	Direct	Reported balance After 2026-02-09 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-02-09 · Disposition to issuer · Disposed 4,246 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $190.00	Direct	Reported balance After 2026-02-09 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-02-09 · Disposition to issuer · Disposed 5,200 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $265.90	Direct	Reported balance After 2026-02-09 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-02-09 · Disposition to issuer · Disposed 1,500 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.90	Direct	Reported balance After 2026-02-09 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-02-09 · Disposition to issuer · Disposed 1,920 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.30	Direct	Reported balance After 2026-02-09 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-02-09 · Disposition to issuer · Disposed 2,500 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.20	Direct	Reported balance After 2026-02-09 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2026-02-09 · Disposition to issuer · Disposed 6,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"),

F2: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.

F3: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an "In-The-Money Option"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time.

F4: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.

Orchard Therapeutics plc

Report date January 24, 2024 · Filed January 24, 2024

Section 16 reporting ended · disclosed 2024-01-24. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	Reported balance After 2024-01-24 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2024-01-24 · Disposition to issuer · Disposed 12,294 · Balance 0 F1: The ordinary shares, nominal value GBP 0.10 per share (the "Ordinary Shares") may be represented by American Depositary Shares ("ADSs"), each of which currently represents ten Ordinary Shares. F2: On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company ("KKC") acquired all outstanding Ordinary Shares of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"). At the effective time of the Scheme of Arrangement, each outstanding Ordinary Share of the Company was exchanged for an amount equal to (a) $1.60 in cash, without interest (the "Cash Consideration"), and (b) one contractual contingent value right (each, a "CVR"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC. F3: (continued) In addition, each ADS of the Company was exchanged for an amount equal to (a) $16.00 in cash (less certain Orchard ADS Fees pursuant to the terms of the deposit agreement, dated as of November 2, 2018, as amended, by and among the Company, Citibank, N.A., as depositary, and all holders and beneficial owners of Orchard ADSs issued thereunder), and (b) 10 CVRs. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.48 · Expires 2032-06-06	Direct	Reported balance After 2024-01-24 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-01-24 · Disposition to issuer · Disposed 46,000 · Balance 0 F2: On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company ("KKC") acquired all outstanding Ordinary Shares of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"). At the effective time of the Scheme of Arrangement, each outstanding Ordinary Share of the Company was exchanged for an amount equal to (a) $1.60 in cash, without interest (the "Cash Consideration"), and (b) one contractual contingent value right (each, a "CVR"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC. F3: (continued) In addition, each ADS of the Company was exchanged for an amount equal to (a) $16.00 in cash (less certain Orchard ADS Fees pursuant to the terms of the deposit agreement, dated as of November 2, 2018, as amended, by and among the Company, Citibank, N.A., as depositary, and all holders and beneficial owners of Orchard ADSs issued thereunder), and (b) 10 CVRs. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023. F4: Pursuant to the Transaction Agreement dated as of October 5, 2023 by and between KKC and the Company, these options were cancelled in exchange for (i) an amount in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR. F1: The ordinary shares, nominal value GBP 0.10 per share (the "Ordinary Shares") may be represented by American Depositary Shares ("ADSs"), each of which currently represents ten Ordinary Shares.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2033-06-13	Direct	Reported balance After 2024-01-24 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-01-24 · Disposition to issuer · Disposed 105,000 · Balance 0 F2: On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company ("KKC") acquired all outstanding Ordinary Shares of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"). At the effective time of the Scheme of Arrangement, each outstanding Ordinary Share of the Company was exchanged for an amount equal to (a) $1.60 in cash, without interest (the "Cash Consideration"), and (b) one contractual contingent value right (each, a "CVR"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC. F3: (continued) In addition, each ADS of the Company was exchanged for an amount equal to (a) $16.00 in cash (less certain Orchard ADS Fees pursuant to the terms of the deposit agreement, dated as of November 2, 2018, as amended, by and among the Company, Citibank, N.A., as depositary, and all holders and beneficial owners of Orchard ADSs issued thereunder), and (b) 10 CVRs. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023. F4: Pursuant to the Transaction Agreement dated as of October 5, 2023 by and between KKC and the Company, these options were cancelled in exchange for (i) an amount in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR. F1: The ordinary shares, nominal value GBP 0.10 per share (the "Ordinary Shares") may be represented by American Depositary Shares ("ADSs"), each of which currently represents ten Ordinary Shares.

Filing footnotes · ownership attribution and instrument terms

F1: The ordinary shares, nominal value GBP 0.10 per share (the "Ordinary Shares") may be represented by American Depositary Shares ("ADSs"), each of which currently represents ten Ordinary Shares.

F2: On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company ("KKC") acquired all outstanding Ordinary Shares of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"). At the effective time of the Scheme of Arrangement, each outstanding Ordinary Share of the Company was exchanged for an amount equal to (a) $1.60 in cash, without interest (the "Cash Consideration"), and (b) one contractual contingent value right (each, a "CVR"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC.

F3: (continued) In addition, each ADS of the Company was exchanged for an amount equal to (a) $16.00 in cash (less certain Orchard ADS Fees pursuant to the terms of the deposit agreement, dated as of November 2, 2018, as amended, by and among the Company, Citibank, N.A., as depositary, and all holders and beneficial owners of Orchard ADSs issued thereunder), and (b) 10 CVRs. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023.

F4: Pursuant to the Transaction Agreement dated as of October 5, 2023 by and between KKC and the Company, these options were cancelled in exchange for (i) an amount in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR.

Vitae Pharmaceuticals, Inc

Report date October 25, 2016 · Filed October 25, 2016

Section 16 reporting ended · disclosed 2016-10-25. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.00 · Expires 2024-09-23	Direct	Reported balance After 2016-10-25 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2016-10-25 · Disposition to issuer · Disposed 17,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F2: This option, which provided for vesting in three equal annual installments following on September 24, 2014, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.43 · Expires 2025-05-27	Direct	Reported balance After 2016-10-25 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2016-10-25 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F3: This option, which is fully vested, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.62 · Expires 2026-05-25	Direct	Reported balance After 2016-10-25 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2016-10-25 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F4: This option, which provided for vesting in four equal quarterly installments following May 26, 2016, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option.

F2: This option, which provided for vesting in three equal annual installments following on September 24, 2014, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above.

F3: This option, which is fully vested, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above.

F4: This option, which provided for vesting in four equal quarterly installments following May 26, 2016, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
December 17, 2020 Filed Dec 18, 2020 16:09 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	10,909	$0.00 Strike: $19.53	$0.00	Disclosure SEC source: 0001179110-20-012096 · edgar.xml · derivative · entry 3 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,909 shares Expires 2026-06-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted on June 23, 2016. This option is fully vested as of the date hereof. Read SEC document
December 17, 2020 Filed Dec 18, 2020 16:09 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	10,909	$117.82	$1,285,298.38	Disclosure SEC source: 0001179110-20-012096 · edgar.xml · nonDerivative · entry 2 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,562 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.31 to $118.23 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
December 17, 2020 Filed Dec 18, 2020 16:09 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	10,909	$19.53	$213,052.77	Disclosure SEC source: 0001179110-20-012096 · edgar.xml · nonDerivative · entry 1 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,471 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 03, 2020 Filed Nov 4, 2020 17:18 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	5,522	$0.00 Strike: $9.46	$0.00	Disclosure SEC source: 0001179110-20-010821 · edgar.xml · derivative · entry 8 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,522 shares Expires 2025-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on March 22, 2015. This option is fully vested as of the date hereof. Read SEC document
November 03, 2020 Filed Nov 4, 2020 17:18 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	694	$95.97	$66,603.18	Disclosure SEC source: 0001179110-20-010821 · edgar.xml · nonDerivative · entry 6 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,562 F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.97 to $95.99 per share. Read SEC document
November 03, 2020 Filed Nov 4, 2020 17:18 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	4,728	$99.10	$468,544.80	Disclosure SEC source: 0001179110-20-010821 · edgar.xml · nonDerivative · entry 5 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,256 F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.00 to $99.68 per share. Read SEC document
November 03, 2020 Filed Nov 4, 2020 17:18 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	100	$100.48	$10,048.00	Disclosure SEC source: 0001179110-20-010821 · edgar.xml · nonDerivative · entry 4 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,984 Read SEC document
November 03, 2020 Filed Nov 4, 2020 17:18 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	5,522	$9.46	$52,238.12	Disclosure SEC source: 0001179110-20-010821 · edgar.xml · nonDerivative · entry 3 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,084 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 02, 2020 Filed Nov 4, 2020 17:18 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	4,478	$0.00 Strike: $9.46	$0.00	Disclosure SEC source: 0001179110-20-010821 · edgar.xml · derivative · entry 7 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,522 Underlying: Common Stock · 4,478 shares Expires 2025-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on March 22, 2015. This option is fully vested as of the date hereof. Read SEC document
November 02, 2020 Filed Nov 4, 2020 17:18 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	4,478	$99.11	$443,814.58	Disclosure SEC source: 0001179110-20-010821 · edgar.xml · nonDerivative · entry 2 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,562 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.00 to $99.61 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) through (3) of this Form 4. Read SEC document
November 02, 2020 Filed Nov 4, 2020 17:18 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	4,478	$9.46	$42,361.88	Disclosure SEC source: 0001179110-20-010821 · edgar.xml · nonDerivative · entry 1 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,040 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
July 29, 2020 Filed Jul 31, 2020 16:55 UTC	Nabriva Therapeutics plc NBRV · Entity 111497	GrantStock Options · Derivative	35,000	$0.00 Strike: $0.79	$0.00	Disclosure SEC source: 0001104659-20-089141 · a4.xml · derivative · entry 2 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Ordinary Shares · 35,000 shares Expires 2030-07-28 F2 · date: The option was granted on July 29, 2020. F3 · derivative.exercise_date: One hundred percent (100%) of the option will vest on July 31, 2021, subject to the reporting person's continued service on the board of directors of Nabriva Therapeutics plc. Read SEC document
July 29, 2020 Filed Jul 31, 2020 16:55 UTC	Nabriva Therapeutics plc NBRV · Entity 111497	GrantOrdinary Shares	17,500	$0.00	$0.00	Disclosure SEC source: 0001104659-20-089141 · a4.xml · nonDerivative · entry 1 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,500 F1 · balance_after: The reported transaction involved the reporting person's receipt of a grant of 17,500 restricted stock units. The total reported in Column 5 includes the 17,500 newly awarded restricted stock units. Read SEC document
June 24, 2020 Filed Jun 26, 2020 16:10 UTC	Blueprint Medicines Corp BPMC · Entity 77326	GrantStock Option (Right to Buy) · Derivative	4,500	$0.00 Strike: $76.24	$0.00	Disclosure SEC source: 0001179110-20-007793 · edgar.xml · derivative · entry 2 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires 2030-06-24 F2 · derivative.exercise_date: This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 24, 2021. Read SEC document
June 24, 2020 Filed Jun 26, 2020 16:10 UTC	Blueprint Medicines Corp BPMC · Entity 77326	GrantCommon Stock	2,250	$0.00	$0.00	Disclosure SEC source: 0001179110-20-007793 · edgar.xml · nonDerivative · entry 1 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,562 F1 · kind: The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 24, 2021. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
June 19, 2020 Filed Jun 23, 2020 16:15 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionRestricted Stock Units · Derivative	1,312	$0.00	$0.00	Disclosure SEC source: 0001179110-20-007719 · edgar.xml · derivative · entry 2 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,312 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: On June 19, 2019, the reporting person was granted 1,312 restricted stock units. These restricted stock units are fully vested. F2 · derivative.expiration_date: On June 19, 2019, the reporting person was granted 1,312 restricted stock units. These restricted stock units are fully vested. Read SEC document
June 19, 2020 Filed Jun 23, 2020 16:15 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	1,312	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-20-007719 · edgar.xml · nonDerivative · entry 1 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,312 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
June 17, 2020 Filed Jun 19, 2020 16:18 UTC	Orchard Therapeutics plc ORTX · Entity 94933	GrantStock Option (Right to Buy) · Derivative	35,000	$0.00 Strike: $7.81	$0.00	Disclosure SEC source: 0001209191-20-037918 · doc4.xml · derivative · entry 1 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Ordinary Shares · 35,000 shares Expires 2030-06-16 F1 · derivative.exercise_date: All of the shares subject to this option vest upon the earlier to occur of June 17, 2021 or the date of the 2021 Annual General Meeting of the Company. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
June 16, 2020 Filed Jun 18, 2020 17:30 UTC	Generation Bio Co. GBIO · Entity 67174	ConversionSeries C Preferred Stock · Derivative	89,423	$0.00	$0.00	Disclosure SEC source: 0000899243-20-017105 · doc4.xml · derivative · entry 3 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,627 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. Read SEC document
June 16, 2020 Filed Jun 18, 2020 17:30 UTC	Generation Bio Co. GBIO · Entity 67174	PurchaseCommon Stock	30,000	$19.00	$570,000.00	Disclosure SEC source: 0000899243-20-017105 · doc4.xml · nonDerivative · entry 2 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,627 Read SEC document
June 16, 2020 Filed Jun 18, 2020 17:30 UTC	Generation Bio Co. GBIO · Entity 67174	ConversionCommon Stock	50,627	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-017105 · doc4.xml · nonDerivative · entry 1 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,627 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. Read SEC document
June 11, 2020 Filed Jun 15, 2020 17:24 UTC	Generation Bio Co. GBIO · Entity 67174	GrantStock Option (right to buy) · Derivative	52,000	$0.00 Strike: $19.00	$0.00	Disclosure SEC source: 0000899243-20-016554 · doc4.xml · derivative · entry 1 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,000 Underlying: Common Stock · 52,000 shares Expires 2030-06-10 F1 · derivative.exercise_date: This option was granted on June 11, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on June 11, 2021 and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document
January 02, 2020 Filed Jan 3, 2020 19:55 UTC	Viking Therapeutics, Inc. VKTX · Entity 4067	GrantStock Option (Right to Buy) · Derivative	22,000	$0.00 Strike: $7.95	$0.00	Disclosure SEC source: 0001209191-20-001419 · doc4.xml · derivative · entry 1 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2030-01-02 Read SEC document
July 31, 2019 Filed Aug 1, 2019 16:19 UTC	Nabriva Therapeutics plc NBRV · Entity 111497	GrantStock Option · Derivative	35,000	$0.00	$0.00	Disclosure SEC source: 0001104659-19-043345 · a4.xml · derivative · entry 1 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Ordinary Shares · 35,000 shares Expires 2029-07-31 F1 · derivative.exercise_price: The exercise price is $2.38 per share. F2 · derivative.exercise_date: This option was granted on July 31, 2019. One hundred percent (100%) of the option will vest on July 31, 2020, subject to the reporting person's continued service on the board of directors of Nabriva Therapeutics plc. Read SEC document
June 20, 2019 Filed Jun 24, 2019 20:08 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	11,818	$0.00 Strike: $9.46	$0.00	Disclosure SEC source: 0001179110-19-008066 · edgar.xml · derivative · entry 5 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 11,818 shares Expires 2025-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on March 22, 2015. This option vested with respect to 1/36th of the shares underlying the option on April 16, 2015 and vested as to an additional 1/36th of the shares underlying the option each month thereafter. Read SEC document
June 20, 2019 Filed Jun 24, 2019 20:08 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	9,271	$94.83	$879,168.93	Disclosure SEC source: 0001179110-19-008066 · edgar.xml · nonDerivative · entry 4 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.63 to $94.89 per share. Read SEC document
June 20, 2019 Filed Jun 24, 2019 20:08 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	1,600	$96.08	$153,728.00	Disclosure SEC source: 0001179110-19-008066 · edgar.xml · nonDerivative · entry 3 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,271 F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.00 to $96.25 per share. Read SEC document
June 20, 2019 Filed Jun 24, 2019 20:08 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	947	$96.69	$91,565.43	Disclosure SEC source: 0001179110-19-008066 · edgar.xml · nonDerivative · entry 2 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,871 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.29 to $97.25 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) through (3) of this Form 4. Read SEC document
June 20, 2019 Filed Jun 24, 2019 20:08 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	11,818	$9.46	$111,798.28	Disclosure SEC source: 0001179110-19-008066 · edgar.xml · nonDerivative · entry 1 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,818 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 19, 2019 Filed Jun 20, 2019 16:39 UTC	Blueprint Medicines Corp BPMC · Entity 77326	GrantRestricted Stock Units · Derivative	1,312	$0.00	$0.00	Disclosure SEC source: 0001179110-19-007986 · edgar.xml · derivative · entry 2 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,312 Underlying: Common Stock · 1,312 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 19, 2020. F3 · derivative.expiration_date: The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 19, 2020. Read SEC document
June 19, 2019 Filed Jun 20, 2019 16:39 UTC	Blueprint Medicines Corp BPMC · Entity 77326	GrantStock Option (Right to Buy) · Derivative	4,875	$0.00 Strike: $96.77	$0.00	Disclosure SEC source: 0001179110-19-007986 · edgar.xml · derivative · entry 1 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,875 Underlying: Common Stock · 4,875 shares Expires 2029-06-19 F1 · derivative.exercise_date: This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 19, 2020. Read SEC document
January 02, 2019 Filed Jan 3, 2019 20:20 UTC	Viking Therapeutics, Inc. VKTX · Entity 4067	GrantStock Option (Right to Buy) · Derivative	22,000	$0.00 Strike: $8.32	$0.00	Disclosure SEC source: 0001209191-19-001558 · doc4.xml · derivative · entry 1 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2029-01-02 Read SEC document
December 24, 2018 Filed Dec 27, 2018 16:05 UTC	Nabriva Therapeutics plc NBRV · Entity 111497	PurchaseOrdinary Shares	53,000	$1.31	$69,430.00	Disclosure SEC source: 0001104659-18-074905 · a4.xml · nonDerivative · entry 1 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,000 Read SEC document
August 01, 2018 Filed Aug 2, 2018 17:53 UTC	Nabriva Therapeutics plc NBRV · Entity 111497	GrantStock Option · Derivative	10,000	$0.00	$0.00	Disclosure SEC source: 0001104659-18-049252 · a4.xml · derivative · entry 1 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Ordinary Shares · 10,000 shares Expires 2028-08-01 F1 · derivative.exercise_price: The exercise price is $2.53 per share. F2 · derivative.exercise_date: The option award was granted on August 1, 2018. The option award will vest in full on August 1, 2019. Read SEC document
June 21, 2018 Filed Jun 25, 2018 16:56 UTC	Blueprint Medicines Corp BPMC · Entity 77326	GrantStock Option (Right to Buy) · Derivative	7,500	$0.00 Strike: $69.79	$0.00	Disclosure SEC source: 0001179110-18-009001 · edgar.xml · derivative · entry 1 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,136 Underlying: Common Stock · 7,500 shares Expires 2028-06-21 F1 · derivative.exercise_date: This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 21, 2019. Read SEC document
May 29, 2018 Filed May 31, 2018 19:02 UTC	Viking Therapeutics, Inc. VKTX · Entity 4067	PurchaseCommon Stock, par value $0.00001 per share	30,000	$5.16	$154,800.00	Disclosure SEC source: 0001209191-18-034490 · doc4.xml · nonDerivative · entry 1 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.06 to $5.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document
May 02, 2018 Filed May 4, 2018 16:06 UTC	Nabriva Therapeutics plc NBRV · Entity 111497	GrantStock Option · Derivative	29,000	$0.00	$0.00	Disclosure SEC source: 0001104659-18-030636 · a4.xml · derivative · entry 1 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,000 Underlying: Ordinary Shares · 29,000 shares Expires 2028-05-02 F1 · derivative.exercise_price: The exercise price is $4.91 per share. F2 · derivative.exercise_date: This option was granted on May 2, 2018. Vesting began on May 2, 2018 and ends on May 2, 2019. One hundred percent (100%) of the option will vest on May 2, 2019. Read SEC document
January 02, 2018 Filed Jan 3, 2018 16:17 UTC	Viking Therapeutics, Inc. VKTX · Entity 4067	GrantStock Option (Right to Buy) · Derivative	16,000	$0.00 Strike: $4.48	$0.00	Disclosure SEC source: 0001209191-18-000848 · doc4.xml · derivative · entry 1 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2028-01-02 Read SEC document
September 15, 2017 Filed Sep 19, 2017 21:33 UTC	Nabriva Therapeutics plc NBRV · Entity 111497	GrantStock Option · Derivative	10,100	$0.00	$0.00	Disclosure SEC source: 0001104659-17-057957 · a4.xml · derivative · entry 1 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,100 Underlying: Ordinary Shares · 10,100 shares Expires 2027-09-15 F1 · derivative.exercise_price: The exercise price is $6.86 per share. F2 · derivative.exercise_date: This option was granted on September 15, 2017. Vesting began on September 15, 2017 and ends on September 15, 2018. One hundred percent (100%) of the option will vest on September 15, 2018. Read SEC document
July 01, 2017 Filed Jul 5, 2017 21:34 UTC	Viking Therapeutics, Inc. VKTX · Entity 4067	GrantStock Option (Right to Buy) · Derivative	40,000	$0.00 Strike: $1.08	$0.00	Disclosure SEC source: 0001209191-17-043855 · doc4.xml · derivative · entry 1 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2027-07-01 Read SEC document
June 23, 2017 Filed Jun 27, 2017 21:56 UTC	Nabriva Therapeutics Legacy plc NBRV · Entity 174291	OtherStock Option · Derivative	10,100	$0.00	$0.00	Disclosure SEC source: 0001104659-17-041906 · a4.xml · derivative · entry 2 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,100 Underlying: Ordinary Shares · 10,100 shares Expires 2026-08-25 F4 · derivative.exercise_price: The exercise price is 6.634 Euro. F2 · kind: Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG. The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc. F5 · derivative.exercise_date: This option was granted on August 26, 2016. Vesting began on August 31, 2016 and ends on August 31, 2017. One hundred percent (100%) of the option will vest on August 31, 2017. Read SEC document
June 23, 2017 Filed Jun 27, 2017 21:56 UTC	Nabriva Therapeutics Legacy plc NBRV · Entity 174291	OtherStock Option · Derivative	16,000	$0.00	$0.00	Disclosure SEC source: 0001104659-17-041906 · a4.xml · derivative · entry 1 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Ordinary Shares · 16,000 shares Expires 2025-07-05 F1 · derivative.exercise_price: The exercise price is 6.618 Euro. F2 · kind: Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG. The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc. F3 · derivative.exercise_date: This option was granted on August 26, 2016. Vesting began on August 31, 2016 and ends on August 31, 2019. This option vests on a monthly pro-rata basis at the end of each successive month following August 31, 2016. Read SEC document
June 21, 2017 Filed Jun 23, 2017 16:21 UTC	Blueprint Medicines Corp BPMC · Entity 77326	GrantStock Option (Right to Buy) · Derivative	10,909	$0.00 Strike: $46.02	$0.00	Disclosure SEC source: 0001179110-17-009516 · edgar.xml · derivative · entry 1 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,636 Underlying: Common Stock · 10,909 shares Expires 2027-06-21 F1 · derivative.exercise_date: This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 21, 2018. Read SEC document
October 25, 2016 Filed Oct 25, 2016 16:34 UTC	Vitae Pharmaceuticals, Inc VTAE · Entity 181526	Disposition to issuerStock Option (Right to Buy) · Derivative	10,000	$11.38 Strike: $9.62	$113,800.00	Disclosure SEC source: 0001104659-16-151949 · a4.xml · derivative · entry 3 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2026-05-25 F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F4 · derivative.exercise_date: This option, which provided for vesting in four equal quarterly installments following May 26, 2016, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above. Read SEC document
October 25, 2016 Filed Oct 25, 2016 16:34 UTC	Vitae Pharmaceuticals, Inc VTAE · Entity 181526	Disposition to issuerStock Option (Right to Buy) · Derivative	10,000	$8.57 Strike: $12.43	$85,700.00	Disclosure SEC source: 0001104659-16-151949 · a4.xml · derivative · entry 2 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2025-05-27 F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F3 · derivative.exercise_date: This option, which is fully vested, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above. Read SEC document
October 25, 2016 Filed Oct 25, 2016 16:34 UTC	Vitae Pharmaceuticals, Inc VTAE · Entity 181526	Disposition to issuerStock Option (Right to Buy) · Derivative	17,000	$13.00 Strike: $8.00	$221,000.00	Disclosure SEC source: 0001104659-16-151949 · a4.xml · derivative · entry 1 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,000 shares Expires 2024-09-23 F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F2 · derivative.exercise_date: This option, which provided for vesting in three equal annual installments following on September 24, 2014, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.